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Oncolytic viruses (OV) are a class of antitumor agents that selectively kill tumor cells
while sparing normal cells. Oncolytic herpes simplex virus (oHSV) has been investigated
in clinical trials for patients with the malignant brain tumor glioblastoma for more than
a decade. These clinical studies have shown the safety of oHSV administration to the
human brain, however, therapeutic efﬁcacy of oHSV as a single treatment remains
unsatisfactory. Factors that could hamper the anti-glioblastoma efﬁcacy of oHSV include:
attenuated potency of oHSV due to deletion or mutation of viral genes involved in
virulence, restricting viral replication and spread within the tumor; suboptimal oHSV
delivery associated with intratumoral injection; virus infection-induced inﬂammatory and
cellular immune responses which could inhibit oHSV replication and promote its clearance;
lack of effective incorporation of oHSV into standard-of-care, and poor knowledge about
the ability of oHSV to target glioblastoma stem cells (GSCs). In an attempt to address these
issues, recent research efforts have been directed at: (1) design of new engineered viruses
to enhance potency, (2) better understanding of the role of the cellular immunity elicited by
oHSV infection of tumors, (3) combinatorial strategies with different antitumor agents with
a mechanistic rationale, (4) “armed” viruses expressing therapeutic transgenes, (5) use of
GSC-derived models in oHSV evaluation, and (6) combinations of these. In this review,
we will describe the current status of oHSV clinical trials for glioblastoma, and discuss
recent research advances and future directions toward successful oHSV-based therapy of
glioblastoma.
Keywords: glioblastoma, oncolytic virus, herpes simplex virus type 1, gene therapy, glioblastoma stem cells,
combination therapy, synergy, molecular targeted therapy
INTRODUCTION
Glioblastoma(GBM)isthemostcommonandaggressiveprimary
brain tumor in adults (Wen and Kesari, 2008). The current stan-
dard treatment for GBM consists of surgical resection followed by
combination of radiotherapy and chemotherapy with the alky-
lating agent temozolomide (TMZ). Despite this multimodality
approach, tumors inevitably recur for which therapeutic options
are limited. Median survival of GBM patients is only 14.6 months
(Stupp et al., 2005) and this remarkably poor outcome has not
improved substantially over the last three decades. Therapeutic
challenges include the invasive and inﬁltrative nature of GBM
growth that makes surgical resection always incomplete, and the
resistance of tumor cells to the conventional cytocidal therapies.
Molecular targeted agents have not achieved an increase in over-
a l ls u r v i v a l( Chinot et al., 2014; Gilbert et al., 2014). Thus, there
is an urgent need to develop novel, effective therapies for this
devastating malignancy.
Oncolytic viruses (OV) have been drawing a great deal
of attention as biological anti-cancer agents, with a distinct
mechanism of action from conventional cancer therapeutics.
OV is a replication competent virus, either genetically engi-
neered or naturally occurring, which selectively replicates in
tumor cells and causes tumor cell death (Russell et al., 2012).
The production of virus progeny leads to secondary infec-
tion and virus spread within the tumor and eventual tumor
destruction. This process, however, proceeds while sparing nor-
mal cells. Selective replication of OV in tumor cells can be
achieved by taking advantage of aberrations found in can-
cer cells, which include defective innate anti-viral and apop-
totic response to viral infection. Thus, viral genes that are
not essential for viral growth but required for viral propa-
gation in normal cells can be mutated or deleted to engen-
der tumor selectivity. Many viruses, including both DNA
[e.g., herpes simplex virus (HSV)] and RNA (e.g., poliovirus)
viruses, have been studied as potential OV platforms for cancer
therapeutics.
For GBM treatment, HSV, adenovirus (Chiocca et al., 2004),
poliovirus (Gromeier et al., 2000; Goetz and Gromeier, 2010),
Newcastle disease virus (Freeman et al., 2006), reovirus (Forsyth
et al., 2008; Kicielinski et al., 2014), parvovirus (Herrero et al.,
2004), and measles virus (Allen et al., 2013) are at different stages
of clinical OV development after preclinical investigations show-
ing anti-GBM activities (Wollmann et al., 2012; Murphy and
Rabkin, 2013). Oncolytic HSV (oHSV) is considered particu-
larly suited and promising for treating GBM. A double stranded
DNA virus containing ∼80 viral genes, HSV type 1 is a human
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pathogen causing illnesses such as encephalitis, therefore use
of HSV as a cancer therapeutic requires genetic engineering.
Historically, oHSV has undergone several generations of genetic
manipulation during its development as an antitumor agent. The
ﬁrst engineered HSV capable of selective replication and killing
GBM was reported by Martuza et al. (1991),w h i c ho p e n e dt h e
door to applying “virotherapy” for GBM. This seminal work fea-
tured an engineered oHSV mutant, dlsptk, which lacks the viral
gene encoding thymidine kinase (Gordon et al., 1983; Martuza
et al., 1991). Neuropathogenicity issues, however, remained with
theseHSV-TKmutants.Thesecondgeneusedtoreduceneurovir-
ulence and confer tumor speciﬁcity was γ34.5, and the deletion
of the both copies of γ34.5 has been commonly employed to cre-
ate oHSVs. The gene product of γ34.5, ICP34.5, recruits protein
phosphatase 1 (PP1) to dephosphorylate eIF2α leading to inhibi-
tion of the protein synthesis shut-off caused by phosphorylated
eIF2α (p-eIF2α), a crucial anti-viral defense mechanism medi-
ated by host RNA-induced protein kinase R (PKR) (He et al.,
1997). ICP34.5 also binds to the mammalian autophagy protein
Beclin 1 to antagonize host autophagy responses (Orvedahl et al.,
2007), and forms a complex with proliferating cell nuclear anti-
gen (PCNA), a protein involved in DNA replication and repair
(Brown et al., 1997). HSV mutants lacking ICP34.5 maintain
the capability of replication in tumor cells where ICP34.5 is not
required for production of infectious progeny, whereas they fail
to replicate in normal neurons where ICP34.5 is essential for
viral replication (MacLean et al., 1991; McKie et al., 1996, 1998).
The third viral gene used to attenuate oHSV is UL39,w h i c h
encodes the large subunit of ribonucleotide reductase (ICP6)
(GoldsteinandWeller,1988;Minetaetal.,1994).ICP6isrequired
for efﬁcient viral growth in non-dividing cells but not in many
dividing cells with abundant dNTP pools or in cells with mutated
p16 (Aghi et al., 2008) .T h es e c o n dg e n e r a t i o no fo H S Vw a s
developed based upon the ﬁrst generation mutants and contains
multiple gene mutations/deletions. G207 has deletions at both
γ34.5 loci and a lacZ gene insertion inactivating the ICP6 gene
(UL39) (Mineta et al., 1995). Some newer oHSVs with additional
properties have been developed based on the mutants indicated
here and include so-called “armed” oHSV carrying therapeutic
transgenes.
oHSV has been shown to be effective for the treatment of a
variety of cancer types as reviewed in (Shen and Nemunaitis,
2006; Liu et al., 2013a), and an oHSV expressing GM-CSF
has demonstrated clinical efﬁcacy in malignant melanoma trials
(Senzer et al., 2009).
Progress in improving oHSV therapy for GBM has been
steady but slow; it is over 20 years since the discovery of the
oncolytic potential of oHSV for GBM therapy, and clinical
exploratory investigations of oHSV began more than a decade
ago. Preclinical and clinical research of oHSV has not only
shown great potential for GBM treatment, but also revealed
drawbacks and limitations of the exiting oHSV strategies and
the need for further reﬁnement. In this article, we will sum-
marize the current status of oHSV in GBM clinical trials, dis-
cuss recently described oHSV strategies, and propose future
directions for successful oHSV application to clinical GBM
therapy.
oHSV CLINICAL TRIALS FOR GBM
HSV1716 is one of the ﬁrst generation engineered oHSVs, with
deletions in both copies of the neurovirulence gene γ34.5 for
selective replication in tumor cells. A series of 3 phase I clinical
trials using HSV1716 were conducted in the UK and reported on
from 2000 to 2004 (Rampling et al., 2000; Papanastassiou et al.,
2002; Harrow et al., 2004). The ﬁrst study evaluated the safety of
intratumoral injection of HSV1716 in 9 patients with recurrent
malignant glioma (Rampling et al., 2000). HSV1716 at doses of
103–105 pfu (plaque forming unit) did not induce adverse clin-
ical symptoms or reactivation of latent HSV, demonstrating the
safety and feasibility of intratumoral administration of HSV1716.
Inthesecondstudy,12patientswithmalignantglioma(including
11 GBM) received an intratumoral injection of 105 pfu HSV1716,
and 4–9 days after inoculation, tumors were removed and assayed
for viral replication (Papanastassiou et al., 2002). HSV1716, in
excess of the input dose, was recovered from the injection site in
2 patients. PCR detected HSV DNA at the sites of inoculation in
10 patients and at distal tumor sites in 4; HSV-speciﬁc antigen
was detected in 2 tumors. Five patients, including 2 sero-negative
cases, showed increases in levels of HSV-speciﬁc IgG and IgM,
indicating an immunological response to HSV1716. This study
for the ﬁrst time demonstrated that oHSV replicates in malig-
nant gliomas without causing toxicity in both HSV-seropositive
and -seronegative patients. The third trial assessed the safety of
HSV1716 injection into the brain adjacent to tumor and the abil-
ity of the virus to eliminate any residual tumor (Harrow et al.,
2004). Twelve patients with recurrent or newly diagnosed high-
grade gliomas underwent tumor resection, and received a total of
105 pfu HSV1716 injected into 8 to 10 sites around the resulting
tumor cavity. There was no clinical evidence of toxicity asso-
ciated with virus administration. Three patients remained alive
and clinically stable at 15–22 months post-surgery and HSV1716
injection, including 1 patient in which magnetic resonance imag-
ing (MRI) demonstrated a reduction of tumor volume over 22
months. This study showed the safety of HSV1716 injection into
the brain adjacent to excised tumor, and potential efﬁcacy of
HSV1716 in glioma patients.
Results of clinical trials using G207 conducted in the US
were published in 2000, 2009, and 2014 (Markert et al., 2000,
2009, 2014). A phase 1 trial designed to determine the safety
of G207 inoculation into gliomas recruited 21 patients with
recurrent malignant gliomas (16 GBMs and 5 anaplastic astrocy-
tomas), and used escalating vector dose from 1 × 106 to 3 × 109
pfu (Markert et al., 2000). No serious toxicity attributable to
G207 was observed. There were radiographic (MRI) and neu-
rological ﬁndings suggestive of anti-tumor activity. In 4 patients
who underwent tumor re-resection after G207 inoculation, PCR
detected G207 DNA in tumors from 2 patients, whose resections
were done 56 and 157 days after inoculation. One GBM patient
who showed tumor regression in post-treatment MRI passed
away due to a stroke 10 months after G207 treatment and autopsy
showed no evidence of GBM.
The following phase 1b study used two inoculations of G207
before and after tumor resection in six patients with recurrent
GBM (Markert et al., 2009). First virus inoculation (1.5 × 108
pfu) was given intratumorally via a catheter, and 2–5 days later
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second virus (1 × 109 pfu) was injected into the brain sur-
rounding the resection cavity immediately following resection.
One patient experienced transient hyperthermia and decreased
responsiveness, which was probably related to G207 administra-
tion into the ventricles. The small sample size rendered efﬁcacy
assessment difﬁcult, but there was no radiographic complete
or partial response and median survival after G207 administra-
tion was 6.6 (2–20.75) months. Viral replication was detected
in 3 patients by RT-PCR and in 5 patients by immunohisto-
chemistry for the late protein gC. However, infectious G207 was
isolatedfromthetumorofonlyonepatient.NosheddingofG207
was detected from serum, conjunctive and saliva. Increases in
mononuclear CD3, CD8 and HAM56+ immune cell inﬁltrates
were noted in post-G207 tissue in the majority of patients. This
study demonstrated the viral replication of G207, and possible
antitumor activity and an overall good safety proﬁle of multiple
dose delivery of G207, including direct inoculation into the brain
adjacent to tumor resection cavities.
Very recently, the results of a phase 1 trial combining G207
with radiation therapy (NCT00157703) were reported (Markert
et al., 2014). Nine recurrent glioma patients (7 GBMs) received
stereotactic intratumoral inoculations of G207 at 109 pfu, and
24h later were treated with single focal irradiation (5 Gy).
Treatment was well tolerated. Three patients showed marked
radiographic responses, and the median survival time from G207
injection until death was 7.5 months. This study showed the
safety and the potential for clinical response of the combinatorial
treatment of G207 and radiation for malignant glioma.
In these clinical trials, the maximum tolerated dose (MTD)
was never reached and the use of these mutant HSVs in human
brain was generally well tolerated. No patient has ever devel-
oped HSV encephalitis. While efﬁcacy evaluation was not a
primary objective of these studies, instances of tumor regres-
sion by MRI or autopsy, and of long-term survival as long
as 22 months after HSV1716 injection are encouraging signs
(Harrow et al., 2004). Tumor resection after viral inoculation
provided evidence for replication of HSV1716 (Papanastassiou
et al., 2002) and G207 (Markert et al., 2009), but at rela-
tively low frequency with 2 of 12 patients (Papanastassiou et al.,
2002) and 3 of 6 patients (Markert et al., 2009), respectively.
This low rate of replication detection may indicate ineffective
replication and spread of oHSV, which could directly com-
promise its efﬁcacy in GBM therapy. These clinical studies
also showed that oHSV injection in the human brain induces
immuneresponses, including sero-conversionand recruitment of
immune cells to the site of oHSV infection (Papanastassiou et al.,
2002; Harrow et al., 2004; Markert et al., 2009). Mononuclear
immune cells such as macrophages and T lymphocytes could
play major and different roles in modulating oHSV efﬁcacy
by prematurely clearing oHSV as innate and adaptive immune
response or by attacking tumor cells as anti-tumor effectors.
In this regard, the information available from these published
studies is preliminary and limited, and future investigations
should decipher the complex interaction of the host immune
system and oHSV infection of GBM. Thus, these clinical trials,
althoughexhibitingpromise,revealedchallengesandunanswered
questions.
In addition to these published trials, ongoing or unpublished
clinical studies testing newer oHSVs for malignant gliomas are
listed in Table 1.G 4 7   is a third generation oHSV created from
G207 with an additional deletion within the nonessential α47
gene. The absence of α47 leads to increased MHC class I expres-
sion, and early expression of Us11 driven by the immediate-early
α47 promoter enhances the growth of γ34.5 mutants (Todo et al.,
2001). rQNestin34.5, a HSV mutant in which one copy of the
γ34.5 gene was reinserted into the UL39-deleted, γ34.5-deleted
viral genome under control of the nestin promoter, exhibits
increased replication in GBM cells (Kambara et al., 2005). M032
has a similar construction as M002, lacking both copies of the
γ34.5 gene and expressing human IL-12 (Roth et al., 2014). All of
these have shown promising safety or antitumor efﬁcacy in pre-
clinical GBM studies, and are currently in active clinical trials or
in preparation for trials.
CURRENT STRATEGIES USING oHSV FOR GBM THERAPY
Since clinical trials have shown apparently limited efﬁcacy of
oHSV for GBM, how to improve efﬁcacy while retaining safety
has become the focus of preclinical and clinical oHSV research.
To this end, recent research efforts have been directed at differ-
ent areas that include: (1) use of GBM cancer stem cell-derived
models in oHSV evaluation, (2) design of new engineered viruses
to enhance potency, (3) better understanding of the role of the
cellular immunity elicited by oHSV infection of tumors, (4)
combinatorial strategies with different antitumor agents with a
mechanistic rationale, and (5) “armed” viruses expressing thera-
peutictransgenes. Inthissection, wewilloverview recent relevant
publications and summarize cutting-edge strategies and advances
toward improving oHSV therapy of GBM.
USE OF GBM STEM CELL-DERIVED MODEL IN oHSV EVALUATION
With increasing knowledge of GBM biology, the propagation
of GBM is thought to be sustained and driven by a subpop-
ulation of neoplastic cells. These cells, termed GBM stem cells
(GSCs), exhibit stem cell-like properties of self-renewal and
multi-potential differentiation, and efﬁciently generate tumors
upon implantation to immunocompromisedmice (Nduom et al.,
2012). GSCs appear to play a key role in tumor invasion, resis-
tance to various treatments, and recurrence (Eyler and Rich,
2008) and thus are considered a critical therapeutic target.
We investigated the efﬁcacy of oHSV with different genetic
mutations against GSCs isolated from surgical specimens of
human GBMs (Wakimoto et al., 2009). Although UL39 (ICP6)
mutant F 6 was as efﬁcacious as wild type strain F, γ34.5-deleted
oHSV such as R3616 and G207 were unable to replicate in GSCs,
exhibitinganattenuatedphenotype.However,additionaldeletion
of α47 reversed this phenotype, as G47  was able to replicate,
spread, and kill both CD133+ and CD133– cells, as well as repress
secondary sphere formation of GSCs. Thus, potency of oHSV
against human GSCs correlated with oHSV mutations. We also
showedthatasingleintratumoralinoculationofG47 prolonged
survival of immunocompromised mice harboring highly invasive
GSC-derived intracranial GBM. Friedman et al also showed that
both CD133+ and CD133− GBM cells are targetable by oHSV,
and that expression of CD111 (nectin-1), an HSV entry receptor,
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Table 1 | Oncolytic herpes simplex viruses in completed and ongoing clinical trials for malignant glioma.
Virus (stain) Country Year* Status Phase Protocol Result References
1716 UK 1996 Closed I Intatumoral, 103–105 pfu,
single injection
Of 9 patients treated, 4 were alive
and well 14–24 months after 1716
administration. No toxicity or
serious adverse events.
Trial ID: UK0033**
(Rampling et al., 2000)
1716 UK 2000 Closed I Intatumoral, 105 pfu, single
injection
No toxicity or serious adverse
events
(Papanastassiou et al.,
2002)
1716 UK 2001 Closed I Adjacent brain, 105 pfu,
single injection
3 out of 12 patients remained
alive and clinically stable at 15–22
months post-surgery and 1716.
No toxicity or serious adverse
events.
(Harrow et al., 2004)
1716 UK 2006 Open II/III Intratumoral Unpublished UK0136**
1716 USA 2013 Open I Intratumoral/Peritumoral Unpublished Trial ID: NCT02031965
G207 USA 1998 Open I Intratumoral, 106 –3× 109
pfu,single injection
8 out of 21 patients with
decreased tumor volume. No
toxicity or serious adverse events.
Trial ID: US0235**
(Markert et al., 2000)
G207 USA 2002 Closed Ib Intratumoral and adjacent
brain, total 1.15 × 109 pfu,
two injections before and
after resection.
Adverse events in 1 of 6 patients. Trial ID: NCT00028158
(Markert et al., 2009)
G207 USA 2005 Closed I Intratumoral injections at
109 pfu, followed by a
single focal irradiation (5
Gy) 24h later.
Marked radiographic response in
3 of 9 patients, with 7 .5 months of
median survival. No toxicity or
serious adverse events.
Trial ID:
NCT00157703 (Markert
et al., 2014)
G47  Japan 2009 Open I/II Stereotactic intratumoral
injections, 2nd injection
follows 5–14 days later.
Unpublished Trial No.:
UMIN000002661
rQNestin–34.5 USA 2011 Open I Peritumoral Unpublished Trial ID: US1100**
M032 USA 2014 Open I Intratumoral, single
injection
Unpublished Trial ID: NCT02062827
*Year approved or initiated.
**According to The Journal of Gene Medicine Clinical Trial site (http://www.abedia.com/wiley/index.html).
isanimportantfactordeterminingsensitivitytooHSV(Friedman
et al., 2009).
GBM contains abundant hypoxic regions that promote the
GSC-like phenotype and confer resistance to chemo- and radio-
therapy (Li et al., 2009; Seidel et al., 2010). Hypoxia was shown
to enhance replication of oHSV G207 in U87 GBM xenografts
in vitro and in vivo (Aghi et al., 2009). Sgubin et al. examined
the therapeutic effects of G47  in patient-derived GSCs under
normoxia and hypoxia (Sgubin et al., 2012). G47  infection of
GSCs was able to counteract hypoxia-mediated enhancement of
thestem-likepropertiesofGSCs,inhibitingtheirself-renewaland
stem cell marker CD133 expression. In orthotopic human GSC
xenografts, inoculation of a G47  derivative, G47 Us11ﬂuc,
demonstrated an equivalent frequency of viral infection and
replication in hypoxic and nonhypoxic tumor areas, highlighting
the ability of oHSV G47  to target GSCs in a hypoxic niche
environment (Sgubin et al., 2012). On the other hand, γ34.5-
deleted oHSV C101 was shown to exhibit reduced replication
and/orcytotoxicityagainstGSC-likehumanxenograftlinesunder
hypoxic as opposed to normoxic conditions despite increased
CD111 (nectin-1) expression mediated by hypoxia (Friedman
et al., 2012).
Unlike human GBM xenografts, syngeneic GBM models in
immunocompetent mice allow critical evaluation of how oHSV-
induced adaptive immune responses impact on oHSV therapy
of GBM. Murine 005 GBM cells, possessing heterozygous Tp53
and activated Ras and Akt, exhibit stem-like properties, includ-
ing high-level expression of mProminin-1 (CD133 equivalent),
and demonstrate histopathological hallmarks of GBM such as
cellular heterogeneity, invasion and hypervascularity (Marumoto
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et al., 2009). This syngeneic GSC model enabled detailed charac-
terization of the multifaceted efﬁcacy of G47 -mIL12, including
assessment of direct oncolysis, regulatory T cell downregulation,
and anti-angiogenesis (Cheema et al., 2013).
DESIGN OF NEW ENGINEERED VIRUSES TO ENHANCE POTENCY
Although oHSVs that lack γ34.5 are capable of replication in
tumor cells, the clinical trials testing HSV1716 and G207 sug-
gested that these γ34.5-null attenuated oHSVs may not be potent
enough to provide substantial efﬁcacy for GBM. Preclinical
research has continued to seek new designs of oHSV that could
achieve both potency and safety. Such approaches include dele-
tionofviralgeneswithpartiallyorfullyintactγ34.5andreceptor-
mediated tumor speciﬁc targeting.
The use of viral gene deletion
Us3encodes aserine-threonine kinase that inhibitsvirus-induced
apoptosis and Akt activation. As apoptotic pathways are fre-
quently dysfunctional in tumor cells, oHSV with a Us3 deletion
replicates preferentially in tumor cells, but induces apoptosis in
normal cells, preventing further replication (Liu et al., 2007).
However, Us3 mutant R7041 is not safe enough for intracere-
bral inoculation. A novel oHSV, MG18L, was constructed that
contains a US3 deletion and an inactivating LacZ insertion in
UL39 (Kanai et al., 2011). MG18L was severely neuroattenu-
ated in mice, replicates well, and activates Akt in human GSCs.
In vivo, intratumoral injection of MG18L had anti-GBM activ-
i t yi na no r t h o t o p i cG S Cx e n o g r a f tm o d e l( Kanai et al., 2011).
Importantly, MG18L like its parental Us3 mutant R7041 was syn-
ergisticwithinhibitorsofphosphatidylinositol3-kinase(PI3K)in
killing tumor cells, and this will be discussed later.
The γ3 4 . 5g e n eo fH S Vp l a y sac e n t r a lr o l ei nn e u -
ropathogenicity and is deleted for tumor selectivity in thus far
all oHSVs clinically evaluated for treating malignant gliomas
(HSV1716 and G207). Unfortunately, deletion of γ34.5 atten-
uates virus replication even in cancer cells, especially human
GSCs (Wakimoto et al., 2009). γ34.5-encoded ICP34.5 is a mul-
tifaceted protein, and one of its diverse functions is to interfere
with autophagy by binding to a cellular protein, Beclin 1 (Atg6)
(Orvedahl et al., 2007). Kanai et al. developed a new oHSV,
 68H-6, with deletion of the γ34.5 Beclin 1 binding domain
(BBD,aa68–87),ratherthanthewholeγ34.5,inadditiontoUL39
(ICP6) inactivation (Kanai et al., 2012b).  68H-6 exhibited min-
imal neuropathogenicity in HSV-susceptible mice as opposed to
single mutants for BBD ( 68H) and UL39 ( 68HR-6) (Kanai
et al., 2012b).  68H-6 replicated well in human glioma cell lines
and GSCs, effectively killing these cells in vitro and prolonging
survival of athymic mice bearing orthotopic human U87 and
GSC-derived tumors (Kanai et al., 2012b). In contrast, γ34.5
deleted 1716 and 1716-6 barely replicated in GSCs. As expected,
infectionof 68H-6or1716-6inducedautophagyingliomacells,
but inhibition of autophagy had no effect on virus replication or
p-eIF2α levels (Kanai et al., 2012b).
Receptor mediated targeting of tumor cells
EGFR gene ampliﬁcation is found in 40% of GBMs and is asso-
ciated with overexpression of epidermal growth factor receptor
(EGFR) and its truncated mutant form, EGFRvIII (Sugawa et al.,
1990; Ekstrand et al., 1992). EGFRvIII presents a tumor speciﬁc
epitope on the cell surface and can be speciﬁcally recognized by
a single chain antibody, MR1-1. An oHSV was engineered by
fusing MR1-1 to the viral glycoprotein gC, an envelope protein
involved in initial virus binding to heparin sulfate on the cell sur-
face(Grandietal.,2010).ThismutantoHSVhad5-foldincreased
infectivity for EGFRvIII-bearing U87 glioma cells compared to
mutant receptor-deﬁcient cells. In vivo, the MR1-1-modiﬁed-gC
oHSV imparted sustained infection of EGFRvIII+ U87 glioma
subcutaneous xenografts (Grandi et al., 2010). Using a similar
strategy, another EGFR-retargeted oHSV was created by intro-
ducing a scFv antibody for human EGFR into a mutant form of
viral glycoprotein gD (Uchida et al., 2013). The retargeted oHSV,
after having another entry accelerating mutation in gB, efﬁciently
and exclusively entered cells that express EGFR. This oHSV, KNE,
demonstrated safety upon intracerebral inoculation in mice and
increased survival in an orthotopic mouse model of human GBM
with up to 73% of animals showing complete response (Uchida
et al., 2013).
R-LM113 is a recombinant HSV created by inserting a scFv
antibody against HER2, human epidermal growth factor 2, into
the gD gene (Menotti et al., 2008). R-LM113 is fully retar-
geted to HER2 since this recombinant HSV lost the ability
to enter cells through the natural gD receptors, HVEM and
nectin-1, but could selectively infect HER2-expressing cells. In
vivo, R-LM113 was safe upon inoculation to the brains of
HSV-permissive mice, and was efﬁcacious against PDGF-induced
malignant glioma as the treatment improved survival of brain
tumor-bearing NOD/SCID and immunocompetent BALB/c mice
(Gambini et al., 2012; Reisoli et al., 2012). Thus, tropism manip-
ulation through retargeting fully replication competent HSV to
GBM-associated receptors might provide an avenue for increased
infectivity and speciﬁcity for the target cell as well as efﬁcacy,
without compromising safety.
Understanding virus and host interaction
Elucidation of tumor host responses to HSV and oncogenic path-
waysthatmodulatevirusreplicationcouldleadtothediscoveryof
oHSV efﬁcacy biomarkers and design of novel oHSVs. Recently,
activated STAT3 signaling, which represents a central hub in
malignant glioma progression and maintenance, was shown to
enhance rQNestin34.5 replication (Okemoto et al., 2013b). This
is likely due to STAT3 inhibition of type 1 interferon responses
in infected glioma cells (Okemoto et al., 2013b). Thus, GBM
with elevated STAT3 may represent a preferable target for oHSV
therapy.
BETTER UNDERSTANDING OF THE ROLE OF THE CELLULAR IMMUNITY
ELICITED BY oHSV INFECTION OF TUMORS
Host immune responses to oHSV have been shown to be a barrier
to efﬁcient viral replication and spread within tumor after ini-
tial infection, which could compromise oHSV therapy for GBM
(Ikeda et al., 1999; Wakimoto et al., 2004; Fulci et al., 2007).
However, the role of different immune cell types and molecular
mechanisms regulating oHSV infection has not been fully elu-
cidated. Alvarez-Breckenridge et al. showed that oHSV infection
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induced rapid recruitment and activation of natural killer (NK)
cells, which led to premature viral clearance and hindrance to
oHSV anti-tumor efﬁcacy in both athymic and immunocompe-
tent mouse models (Alvarez-Breckenridge et al., 2012b). Human
NK cells preferentially killed oHSV-infected GBM cells through
the interaction between natural cytotoxicity receptors (NCR)
NKp30 and NKp46 on NK cells and their ligands on infected
GBM cells (Alvarez-Breckenridge et al., 2012b). oHSV titers and
efﬁcacy were increased in GBM in Ncr1−/− mice. Therefore,
oHSV therapy of GBM is partly limited by an antiviral NK cell
response involving speciﬁc NCRs, uncovering novel potential tar-
gets to enhance oHSV cancer therapy. The same group led by
Dr. Chiocca further demonstrated that NK cell action against
oHSV-infected GBM cells was lessened by the histone deacety-
lase inhibitor valproic acid through inhibition of STAT5/T-BET
signaling and generation of γ-interferon (Alvarez-Breckenridge
et al., 2012a). Given that valproic acid is being used in the clinic
as an anti-convulsant, this observation is signiﬁcant in open-
i n gu pa no p p o r t u n i t yf o rp h a r m a c o l o g i c a lm o d i ﬁ c a t i o no ft h e
innate immune response to oHSV to enhance virus replication
and efﬁcacy in humans.
The cellular immune response to oHSV is a complex phe-
nomenon involving innate immunity to oHSV that is likely
deleterious to efﬁcacy and the subsequent adaptive anti-tumor
response that is beneﬁcial. Indeed oHSV infection of tumors acts
as an in situ vaccination to elicit tumor speciﬁc T lymphocytes
effector responses (Toda et al., 1999). Such an approach to induc-
ing anti-tumor immunity by oHSV can be further boosted by
taking advantage of oHSV as a gene delivery vector and express-
ingimmuneenhancingfactors.Tworecentpublicationsdescribed
new armed oHSVs expressing murine fms-like tyrosine kinase
3 ligand (Flt3L) and IL12 (Barnard et al., 2012; Cheema et al.,
2013), and showed their efﬁcacy to be superior to control oHSV
in syngeneic mouse GBM models, underscoring the utility of
the immune activating strategy. These strategies will be discussed
later in the “armed oHSV” section.
COMBINATIONAL STRATEGIES WITH DIFFERENT ANTITUMOR AGENTS
WITH A MECHANISTIC RATIONALE
The history of cancer therapy development has demonstrated
that combinations of multiple anti-cancer modalities are often
more efﬁcacious than each single treatment for refractory cancer.
Successful targeting of GBM, with its heterogeneity, invasiveness,
and multiple oncogenic pathways, likely requires such multi-
modal approaches. Recent research has uncovered promising
combinatorialapproachesemployingoHSVandotheragentsthat
are mechanism-based and often exhibit synergistic anti-cancer
effects (Kanai and Rabkin, 2013).
Combination with conventional therapy
How to incorporate oHSV into the existing standard of care for
GBM is a practical and important issue from the perspective
of oHSV translation to the clinic. Currently used radiation and
TMZ chemotherapy are both genotoxic, while HSV infection also
elicits cellular DNA damage responses to facilitate viral replica-
tion (Taylor and Knipe, 2004; Lilley et al., 2005; Chaurushiya
and Weitzman, 2009). This implies that DNA damage inducers
currently used for GBM and oHSV can modulate common
DNA repair signaling and provide synergistic impact on cell
death.
Previously, TMZ-induced tumor-protective DNA repair path-
ways, involving cellular GADD34 and ribonucleotide reduc-
tase, were shown to enhance oHSV G207-mediated oncolysis
in glioma cells (Aghi et al., 2006). Subsequently, Kanai et al
reported that G47  acts synergistically with TMZ in killing
human GSCs through oHSV-mediated manipulation of DNA
damage responses (Kanai et al., 2012a). Mechanistically, activated
ataxia telangiectasia mutated (ATM) was found to be a crucial
mediator of synergy. Upon G47  infection, activated ATM relo-
calized to HSV DNA replication compartments where it likely
enhanced oHSV replication but could not participate in repairing
TMZ-induced DNA damage, resulting in extensive DNA damage
and cell death. For TMZ-resistant GBM cells expressing O6-
methylbenzylguanine DNA methyltransferase (MGMT), G47 
and TMZ were still synergistic in the presence of an MGMT
antagonist (Kanai et al., 2012a). Combined G47  and TMZ
treatment induced robust DNA damage and markedly extended
survival of mice bearing MGMT-negative GSC-derived intracra-
nial tumors at TMZ doses attainable in patients. Triple com-
bination therapy with MGMT antagonist was effective against
MGMT-positive orthotopic xenografts (Kanai et al., 2012a).
G47  was also combined with etoposide, a topoisomerase
2 inhibitor, and the combination showed moderate synergy in
killing human GSCs and GBM cell lines (Cheema et al., 2011).
This combination did not enhance virus replication, but signif-
icantly increased caspase-mediated apoptosis. In vivo,t h ec o m -
bined treatment of a single cycle of low-dose etoposide with
intratumoral G47  injection signiﬁcantly extended survival of
athymic mice bearing intracranial human GSC-derived tumors
over each single treatment (Cheema et al., 2011).
The combination of OV with ionizing radiation (IR) has
been shown to increase therapeutic efﬁcacy through viral inter-
ference with DNA repair following irradiation of glioma cells
(Hadjipanayis and DeLuca, 2005) and enhanced viral replica-
tion by IR (Advani et al., 2006). When combined with IR, γ34.5
mutant oHSV resulted in increased viral replication and anti-
tumor effects in murine glioma models (Advani et al., 1998).
Advani et al. used γ34.5-deleted HSV-1 carrying a late promoter
driven luciferase in U87 glioma xenografts and administered IR
before or after viral injection to determine optimal temporal
sequencing (Advani et al., 2011). Delivering radiation 6–9h after
oHSV injection, i.e., coinciding with the onset of late viral gene
expression, resulted in the greatest luciferase expression, infec-
tious virus production, and tumor-xenograft regression (Advani
et al., 2011). Therefore, when combined with oHSV, IR adminis-
tration at an optimal time during the HSV replicative cycle may
maximize the combination effect.
Combination with molecularly targeted agents
Molecular analysis of GBMs has shown that genetic alterations in
the PI3K/Akt pathway occur in about 80% of tumors (Parsons
et al., 2008). These molecular changes confer GBMs with pro-
liferative and survival advantages and thus offer an important
target for GBM therapy. oHSV MG18L has a deletion of US3
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which results in Akt activation (phosphorylation) in infected
GBM cells. Combination of MG18L and PI3K or Akt inhibitors
(e.g., LY294002, GDC-0941 and Triciribine) was synergistic in
killing GSCs and glioma cell lines, but not human astrocytes,
through enhanced induction of apoptosis (Kanai et al., 2011).
In vivo, the combination signiﬁcantly prolonged survival of mice
bearing orthotopic GBM xenografts, as compared to either agent
alone, through enhanced induction of apoptosis (Kanai et al.,
2011).Thisisagoodexampleofamechanism-basedcombination
strategy that exploits oHSV-mediated alteration of an oncogenic
signaling pathway in tumor cells.
Combination with anti-angiogenic agents
One of the pathological hallmarks of GBM is marked neovas-
cularity, which is considered to promote GBM progression (Das
and Marsden, 2013). As an adjuvant strategy to treat GBM, anti-
angiogenictherapyhasbeenextensivelyinvestigatedinpreclinical
and clinical studies (Gerstner and Batchelor, 2012).
An angiostatic peptide, cyclic Arg-Gly-Asp (cRGD, cilen-
gitide), binds to and blocks integrins (Brooks et al., 1994;
Friedlander et al., 1995) that are highly expressed on tumor-
associated endothelial cells. Cilengitide pretreatment of immuno-
competent rats bearing orthotopic GBM enhanced treatment
with the UL39 mutant oHSV hrR3 (Kurozumi et al., 2007). hrR3
titer was elevated with the cilengitide pretreatment through the
reduction of tumor vascular permeability, immune cell inﬁltra-
tion, and γ-interferon production. These observations were con-
sistent with the ﬁnding that suppression of macrophage inﬁltra-
tion into brain tumors enhances oHSV ampliﬁcation and spread
(Fulciet al.,2007).Cilengitidewasalso usedwithaγ34.5-deleted,
UL39-disrupted oHSV, rHSVQ, modiﬁed to express vasculostatin
(Vstat120), the fragment of brain-speciﬁc angiogenesis inhibitor-
1 (BAI1), to treat GBM (Fujii et al., 2013). In vitro,t r e a t m e n t
with the armed oHSV, named RAMBO (Hardcastle et al., 2010),
plus cilengitide enhanced the inhibition of endothelial tube for-
mation and mediated synergistic cytotoxicity on glioma cells. In
vivo, combination therapy signiﬁcantly increased the survival of
GBM-bearing athymic mice compared with RAMBO or cilengi-
tide monotherapy (Fujii et al., 2013). Thus, cilengitide enhanced
vasculostatin-expressing virus therapy for malignant glioma.
Zhang et al demonstrated another successful example of com-
bining two agents with anti-angiogenic properties (Zhang et al.,
2012). In athymic mice bearing intracerebral U87 GBM, systemic
administration of Bevacizumab, a monoclonal antibody directed
at VEGF, increased spread of G47 -mAngio, G47  oHSV engi-
neered to secrete anti-angiogenic protein murine angiostatin,
as well as the anti-angiogenic effect. Multimodal therapy using
Bevacizumab plus G47 -mAngio increased animal survival over
each monotherapy alone, which was associated with reduction of
collagenandmatrixmetalloproteinases(MMP)2and9intumors
(Zhang et al., 2012).
Others
rQNestin34.5 is a genetically modiﬁed version of oHSV
rHSVQ with a nestin promoter/enhancer driving expression
of a single copy of γ34.5, rendering an increased ability
to replicate (Kambara et al., 2005). However, this promoter
becomes extensively methylated in infected glioma cells, reduc-
ing ICP34.5 expression and oncolytic potency. Okemoto al.
used demethylating drugs to determine if they improve the
efﬁcacy of rQNestin34.5 therapy in malignant glioma models
(Okemoto et al., 2013a). 5-Aza improved rQNestin34.5 replica-
tion and tumor cell lysis in vitro. In vivo, intratumoral injec-
tion of rQNestin34.5 mixed with demethylating agents, 5-Aza
or decitabine (5-aza-2 -deoxycytidine), signiﬁcantly prolonged
the survival of athymic mice harboring intracranial human
glioma xenografts over single agents alone. Interestingly, val-
proic acid also demethylated the nestin promoter and increased
rQNestin34.5 replication (Okemoto et al., 2013a).
Copper in serum supports angiogenesis (Soncin et al., 1997;
Hu, 1998) and inhibits replication of wild-type HSV-1 (Shishkov
et al., 1997). Copper chelators are currently being investi-
gated as an antiangiogenic and antineoplastic agent for cancer
patients (Lin et al., 2013). Yoo et al showed that physiologi-
cally relevant concentrations of copper (1mg/L) inhibits oHSV
rQNestin34.5 infection and replication, and copper chelation
with ATN-224 reversed this copper-mediated oHSV inhibition
(Yoo et al., 2012). In vivo, systemic administration of ATN-
224augmentedtherapeuticefﬁcacyofintratumoralrQNestin34.5
against intracranial GBM in athymic mice, which was associated
with reduced vascular leakiness (Ktrans) and blood vessel den-
sity, suggesting anti-angiogenic effects by ATN-224 (Yoo et al.,
2012). Importantly, systemic ATN-224 enhanced delivery and
efﬁcacy of systemically administered oHSV hrR3, as the combi-
nation signiﬁcantly reduced tumor growth likely through ATN-
224-mediated increased stability of oHSV in serum (Yoo et al.,
2012).
“ARMED” VIRUSES EXPRESSING THERAPEUTIC TRANSGENES
The presence of genes not essential for virus replication allows
oHSV to accommodate relatively large sizes of exogenous DNA.
oHSV engineered to carry therapeutic genes, so-called “armed
oHSV,” has been used to deliver and express therapeutic pro-
t e i n si nt u m o rc e l l si na na t t e m p tt oe n h a n c ea n t i t u m o re f ﬁ c a c y .
The following sections will discuss recently described strategies in
which “armed” oHSVs play a central role.
Immunomodulating genes
GBM promotes an immunosuppressive tumor microenviron-
ment and the immune status of GBM patients is compromised
(Rolle et al., 2012). oHSV can function as an “in situ vaccina-
tion” since oHSV-mediated tumor cell killing elicits anti-tumor
immunity (Toda et al., 1999). Although stimulation of inﬂamma-
tion can lead to virus clearance before its ampliﬁcation, strategies
to enhance oHSV efﬁcacy by expressing cytokines with immune
activation properties appear promising.
Interleukin 12 is a prominent Th1 response inducer and
known to promote anti-tumor cellular immunity. Expression of
IL-12 in the context of oHSV enhances efﬁcacy in the treat-
ment of murine model of GBM (Hellums et al., 2005). Cheema
et al. further demonstrated the utility of a murine IL12 armed
oHSV, G47 -mIL12, in an immunocompetent murine GSC
model (Cheema et al., 2013). G47 -mIL12 infects and replicates
similarly to the unarmed oHSV counterpart in vitro,w h e r e a si t
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signiﬁcantly enhances survival in syngeneic mice bearing intrac-
erebral 005 GBMs in vivo (Cheema et al., 2013). Mechanistically,
G47 -mIL12 evoked multifaceted beneﬁcial responses including
increased IFN-γ release, anti-angiogenesis, and reduction of reg-
ulatory T cell inﬁltration to the tumor microenvironment. In vivo
NK cell depletion and use of athymic mice revealed the require-
ment of T, but not NK cells for the efﬁcacy of G47 -mIL12
(Cheema et al., 2013). Using the same HSV backbone, G47 -
Flt3L was created to stimulate anti-tumor immunity through
on site expression of soluble Flt3L, a cytokine capable of differ-
entiating hematopoietic precursors into plasmacytoid and con-
ventional dendritic cells (DCs) and mobilizing them from bone
marrow (Barnard et al., 2012). In culture, high levels of Flt3L
expressed by G47 -Flt3L did not affect viral replication or a
cytotoxic effect on glioma cells. Direct inoculation of G47 -
Flt3L into intracerebral CT2A gliomas in C57BL/6 mice resulted
in detectable levels of Flt3L in the blood and was superior to
parental G47  in prolonging survival of animals (Barnard et al.,
2012).
A study examining the safety and biodistribution of M032, a
γ34.5-deleted oHSV expressing human IL-12, in HSV-susceptible
Aotus nonhuman primates was described very recently (Roth
et al., 2014). A single intracerebral inoculation of 106 or 108 pfu
of M032 caused temporary slight body weight loss and mild to
moderate inﬂammatory reactions in the brain, but was overall
well tolerated. Viral DNA was detected in the brain and, at lower
levels, in the spleen up to 91-day post inoculation (Roth et al.,
2014).
Anti-angiogenic genes
Anti-angiogenic therapy targets neovasculature within the tumor
microenvironment. A number of secreted proteins capable of
inhibiting tumor-associated neo-angiogenesis have been iden-
tiﬁed, and used to arm oHSV to enhance overall efﬁcacy
through dual targeting of tumor cells and stromal vascular
cells.
An oncolytic HSV (γ34.5-, ICP6-) carrying an endostatin-
angiostatin fusion gene (VAE) killed GSCs and the expression of
endo-angio inhibited proliferation of human brain microvascu-
lar endothelial cells (HBMEC) compared to control oHSV (Zhu
et al., 2011). In vivo, intratumoral injection of VAE extended
survival of mice harboring intracerebral human GSC xenografts
compared with control monotherapies, non-transgene encoding
rHSV-1 or recombinant endostatin (Zhang et al., 2014).
Angiostatin is an antiangiogenic polypeptide, while
interleukin-12 (IL-12) is an immunostimulatory cytokine
with anti-angiogenic effects. A unique combination strategy
using oHSVs expressing angiostatin (G47 -mAngio) and IL-12
(G47 -mIL12) was tested in orthotopic human GBM xenograft
models (Zhang et al., 2013). Intratumoral injection of G47 -
mAngio and G47 -mIL12 together in mice bearing intracranial
U87 or GSCs-derived tumors signiﬁcantly prolonged survival
compared to each armed oHSV alone. This was associated with
increased anti-angiogenesis and virus spread, as well as decreased
macrophage inﬁltration (Zhang et al., 2013). These data support
the use of oHSVs expressing multiple anti-angiogenic factors to
improve efﬁcacy in GBM.
Prodrug-activating genes
Prodrug-activating gene or suicide gene therapy uses the sys-
temicdeliveryofaninactiveprodrugcoupledwithtumor-speciﬁc
expression of a drug-activating enzyme (the suicide gene), which
convertsthenontoxicprodrugtocytotoxicmetabolitesandcauses
tumor cell death (Duarte et al., 2012). Owning to limited off-site
presence of the toxic substance, this strategy can negate seri-
ous adverse effects on normal tissues associated with systemic
chemotherapy. oHSV armed with prodrug-activating genes not
only exerts direct oncolytic killing but also produces bystander
effects mediated by cytotoxic metabolites released from oHSV-
infected cells.
MGH2, derived from MGH1 containing deletions of both
copies of γ34.5 and an inactivating insertion in UL39, carries
two prodrug-activating transgenes: the cytochrome P450 2B1
(CYP2B1) and the secreted human intestinal carboxylesterase
(shiCE) (Tyminski et al., 2005). CYP2B1 converts cyclophos-
phamide (CPA) into the active DNA-alkylating metabolite,
phosphoramide mustard (PM), and shiCE activates irinotecan
(CPT11) to the active topoisomerase 1 inhibitor, SN-38, in target
cells. MGH2 exhibited anti-tumor activity against human glioma
cells both invitroandinvivo,whichwasenhancedbytheaddition
of CPA and CPT11 (Tyminski et al., 2005). For clinical transla-
tion, Dr. Chiocca’s group created MGH2.1 by removing the GFP
expression cassette from MGH2, and performed toxicology and
biodistribution studies (Kasai et al., 2013). After intracerebral
injection in BALB/c mice, MGH2.1 DNA was detected in brains
for up to 60 days, and expression of virally encoded genes was
restricted to brain. Intracranial inoculation of MGH2.1 induced
a small increase in serum IL-6 levels and did not cause lethality in
HSV-permissive BALB/C mice at 108 pfu without prodrugs and
at 106 with prodrugs. These safety and toxicology data justify a
clinical trial of intratumoral injection of MGH2.1 with peripheral
administration of CPA and/or CPT11 in patients with malignant
gliomas.
Pro-apoptotic genes
Apoptotic pathways are often dysregulated in tumors, including
GBM, and apoptosis induction with pro-apoptotic gene transfer
h a sb e e ni n v e s t i g a t e da sa na n t i - G B Ms t r a t e g y( Abe et al., 2002;
Lee et al., 2002). However, HSV, like other viruses, has inherent
mechanisms that prevent host cells from undergoing premature
apoptosis to sustain replication (Koyama and Miwa, 1997; Aubert
and Blaho, 1999), and expressing exogenous apoptosis-inducing
gene in the context of oHSV had not been explored till recently.
Tamura et al. created a recombinant G47  oHSV that
bears a transgene encoding a secretable TRAIL (tumor necrosis
factor-related apoptosis-inducing ligand) (Tamura et al., 2013).
ThisoHSV-TRAIL(G47 -TRAIL)showedenhancedcytotoxicity
againstTRAIL-oroHSV-resistantGBMcellscomparedtocontrol
oHSV without transgene. oHSV-TRAIL downregulated extra-
cellular signal-regulated protein kinase (ERK)-mitogen-activated
protein kinase (MAPK) and upregulated c-Jun N-terminal kinase
(JNK) and p38-MAPK signaling, and induced resistant GBM
cells to undergo apoptosis via activation of caspase-8, -9, and -3
(Tamura et al., 2013). Furthermore, intratumoral inoculation
of oHSV-TRAIL inhibited tumor invasiveness, and increased
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survival of SCID mice bearing oHSV-resistant intracerebral
GBMs (Tamura et al., 2013), revealing the unique efﬁcacy of
G47 -TRAIL for treatment-refractory GBM.
SUMMARY AND FUTURE DIRECTION
oHSV-based treatment of GBM proceeds through a dynamic,
complex process that involves virus infection, replication and
spread, and activation of inﬂammatory and immune responses
as well as modulation of tumor microenvironments. As we dis-
cussed, these variable aspects of oHSV therapy provide a variety
of opportunities for interventions to improve overall efﬁcacy and
maintain safety. Furthermore, oHSV-mediated activation of cel-
lular pathways such DNA repair response and PI3K/Akt pathway
can be exploited by combinatorial approaches to enhance tumor
cell death. In a simpliﬁed view, the process that takes place during
oHSV-based therapy can be divided into two phases (Figure 1).
In phase 1, oHSV infects GBM cells, replicates, produces progeny
and spreads within the tumor, resulting in oncolytic death of
infected tumor cells. In subsequent phase 2, different strategies
could be summoned that include activation of anti-tumor immu-
nity and apoptosis induction in an attempt to eliminate residual
unaffected part of the tumor with the goal to prevent relapse and
enhance overall efﬁcacy.
One major factor determining the success during phase 1 is
delivery of therapeutic virus, which we did not discuss in detail
in this article. Direct injection into tumor or brain surround-
ing the resection cavity is the only delivery method clinical trials
have utilized. Although this approach enables oHSV to get into
tumor bypassing the blood-brain barrier, there remains an issue
how to deliver oHSV to tumor cells distant from the injection
1. Potent oHSV with partially or fully intact  34.5 and tumor 
selectivity (EGFR targeting, Us3 mutant,  34.5 Beclin1-
binding domain mutant, rQnestin34.5 etc)
2. Delivery improvement (intratumoral, CED, carrier cell, 
intravascular?)
3. Innate immune suppression (valproic acid, 
cyclophosphamide)
4. Inhibition of tumor-associated vasculature (cilengitide, 
bevacizumab)
5. Incorporation into standard care (combination with 
radiation) 
Phase 1 
Phase 2 
1. Incorporation into standard care (combination with 
temozolomide) 
2. Induction of apoptosis (combination with etoposide, Us3 
mutant+PI3K inhibitor, oHSV-TRAIL, oHSV-prodrug-
activating genes + prodrugs)
3. Induction of anti-tumor immunity (oHSV-IL12, oHSV-flt3L)
4. Anti-angiogenesis (bevacizumab, oHSV-angiostatin, 
oHSV-IL12)
1
2 5
2 2 2 2 2
1 1 1 1
3
oHSV
Tumor cells (viable and uninfected)
Infected or affected tumor cells (dying)
Immune or inflammatory cells (e.g. NK 
cells, T cells, macrophages)  
Suppressed innate immune cells 
Tumor-associated blood vessels
Targeted blood vessels
Radiation
Temozolomide
Chemical agents (e.g., valproic
acid, PI3K inhibitor, prodrug) 
Immune-stimulatory cytokines
Anti-angiogenic proteins
3 3 3
FIGURE 1 | Two-phasic process that oHSV-based strategies go through toward successful GBM tumor elimination. For each phase, representative
interventional approaches that we discussed in the text are listed on the right.
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site. Convection-enhanced delivery (CED) (Debinski and Tatter,
2009) may enhance spatial distribution of intracerebrally injected
oHSV (Hadjipanayis et al., 2008). Taking advantage of their
capacity to home to tumors, neural or mesenchymal stem cells
havebeenusedasavehicleforOV(Herrlingeretal.,2000;Ahmed
et al., 2011; Duebgen et al., 2014). Virus-loaded stem cells can
migrateandreleasevirusattumorsitesdistantfromtheinjection.
Inaddition,cell-carriedvirusesappeartobeprotectedfromclear-
ance by cellular immunity. Intravascular delivery, either systemic
intravenous or via carotid arterial, have been attempted for oHSV
(Ikeda et al., 1999; Shikano et al., 2011) and other viruses (Liu
et al., 2013b), and this approach may be worth revisiting with the
aid of compounds such as CPA, valproic acid or copper chelator.
As summarized in Figure 1,w eh a v en o wg a i n e ds u b s t a n -
tive knowledge about an array of strategies that could be useful
to improve oHSV efﬁcacy for GBM in the clinic. It is possible
that achieving both efﬁcient oHSV distribution within tumor
(phase 1) and induction of extensive death of cells including
oHSV-uninfected cells (phase 2) is necessary to obtain substantial
efﬁcacy. This could entail combined use of distinct and diverse
approaches that include more potent but tumor-selective virus,
current standard of care, anti-angiogenic agents, innate immune
suppressors or molecular targeted agents, and on-site expres-
sion of therapeutic transgenes. The sequence and timing of each
treatment may need careful consideration to optimize impacts.
Becausenumerouscombinationsarenowavailable,howtodesign
feasible and mechanistically reasonable protocols aimed at efﬁ-
cient assessment of both safety and efﬁcacy has become a signiﬁ-
cant challenge in clinical translation of novel oHSV strategies.
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